The immunogenicity of single and combination DNA vaccines against tuberculosis

Vaccine

Volumn 18, Issue 20, 2000, Pages 2155-2163

  Morris, Sheldon ^a   Kelley, Cynthia ^a   Howard, Angela ^a   Li, Zhongming ^a   Collins, Frank ^a  

^a Center for Biologics Evaluation/Res   (United States)

Author keywords

Combination vaccines; DNA vaccines; Tuberculosis

Indexed keywords

BCG VACCINE; DNA VACCINE; MYCOBACTERIUM ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; LUNG TUBERCULOSIS; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROVOCATION TEST; TUBERCULOSIS;

AEROSOLS; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BCG VACCINE; FEMALE; IMMUNITY, CELLULAR; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; INJECTIONS, INTRAMUSCULAR; INTERFERON TYPE II; MICE; MICE, INBRED C57BL; MYCOBACTERIUM TUBERCULOSIS; SPECIFIC PATHOGEN-FREE ORGANISMS; TUBERCULOSIS; VACCINATION; VACCINES, DNA;

EID: 0034010994     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00540-X     Document Type: Article

References (42)

1. Dolin P.L., Ravigliane M.C., Kochi A. Global tuberculosis incidence and mortality during 1990-2000. Bull. World Hlth. Org. 72:1994;213-220.
2. World Health Organization. The world health report. 1998;WHO, Geneva.
3. World Health Organization. Anti-tuberculosis drug resistance in the world. The WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance. 1997;WHO, Geneva.
4. Elliot A.M., Halwindii B., Hayes R., Luo N., Mwinga A.G., Tembo G., Machiels L., Steenbergen G., Pobee J., Nunn P., McAdam K. The impact of human immunodeficiency virus on mortality of patients treated for tuberculosis in a cohort study in Zambia. Trans. R. Soc. Trop. Med. Hyg. 89:1995;78-82.
5. Chintu C., Mwinga A. An African perspective on the threat of tuberculosis and HIV/AIDS - can despair be turned to hope? Lancet. 353:1999;997.
6. Colditz G.A., Brewer T.F., Berkey C.S., Wilson M.E., Burdick E., Fineberg H.V., Mosteller F. Efficacy of BCG vaccine in the prevention of tuberculosis: meta analysis of the published literature. JAMA. 271:1994;698-702.
7. Karonga Prevention Trial Group. Randomized controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet. 348:1996;17-24.
8. Donnelly J.J., Ulmer J.B., Shiver J.W., Liu M.A. DNA vaccines. Annu. Rev. Immunol. 15:1997;617-648.
9. Huygen K. DNA vaccines: application to tuberculosis. Int. J. Tub. Lung Dis. 2:1998;971-978.
10. Jacobs G.G., Johnson J.L., Wallis R.S., Whalen C.C., Ginsberg A.M. Tuberculosis vaccines: how close to human testing? Tubercle Lung Dis. 78:1997;159-169.
11. Andersen P. Host responses and antigens involved in protective immunity to Mycobacterium tuberculosis. Scand. J. Immunol. 45:1997;115-131.
12. Huygen K., Content J., Denis O., Montgomery D.L., Yawman A.M., Deck R.R., Dewitt C.M., Drene I.A., Baldwin S., D'Souza C., Deowart A., Lozes E., Vandenbussche P., van Vooren J.P., Liu M., Ulmer J.B. Immunogenic and protective efficacy of a tuberculosis DNA vaccine. Nature Med. 2:1996;893-898.
13. Lowrie D.B., Silva C.L., Colston M.J., Ragno S., Tascon R.E. Protection against tuberculosis by a plasmid DNA vaccine. Vaccine. 15:1997;834-838.
14. Kamath A.T., Feng C.G., Macdonald M., Briscoe H., Britton W.J. Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis. Infect. Immun. 67:1999;1702-1707.
15. Li Z., Howard A., Kelley C., Delogu G., Collins F., Morris S. The immunogenicity of DNA vaccines expressing tuberculosis proteins fused to TPA signal sequences. Infect. Immun. 67:1999;4780-4786.
16. Tanghe A., Lefevre P., Denis O., D'Souza S., Braibant M., Lozes E., Singh M., Montgomery D., Content J., Huygen K. Immunogenicity and protective efficacy of tuberculosis DNA vaccines encoding putative phosphate transport receptors. J. Immunol. 162:1999;1113-1119.
17. Haslov K, Andersen AB, Ljundvist L, Bentzan MW. Comparison of the immunological activity of five defined antigens from Myobacterium tuberculosis in seven inbred guinea pig strains. Scand J Immunol 31:503-10.
18. Espitia C., Espinosa R., Saavedra R., Mancilla R., Romain F., Laqueyrerie A., Merano C. Antigenic and structural similarities between the Mycobacterium tuberculosis 50 and 55-kilodalton and Mycobacterium bovis BCG 45 to 47-kilodalton antigens. Infect. Immun. 63:1995;580-584.
19. Manea C., Lyaschenko K., Wiker H.G., Usai D., Colangeli R., Gennaro M.L. Molecular cloning, purification, and serological characterization of MPT-63, a novel antigen secreted by Mycobacterium tuberculosis. Infect. Immun. 65:1997;16-23.
20. Hewinson RG, Michell SL, Russell WP, McAdam RA, Jacobs WR. Molecular characterization of MPT83: a seroreactive antigen of Mycobacterium tuberculosis with homology to MPT70. Scand J Immunol 1996;490-9.
21. Yuan Y., Crane D.D., Simpson R.M., Zhu Y., Hickey M.J., Sherman D.R., Barry C.E. The 16-kDa a-crystallin (Acr) protein of Mycobacterium tuberculosis is required for growth in macrophages. Proc. Natl Acad. Sci. USA. 95:1998;9578-9583.
22. Yasutomi Y., Robinson H.L., Lu S., Mustafa F., Lekutis C., Arthos J., Mullins J.I., Voss G., Munson K., Wyand M., Letvin N.L. Simian immunodeficiency virus-specific cytotoxic T-lymphocyte induction through DNA vaccination of rhesus monkeys. J. Virol. 70:1996;6780-6810.
23. Klinman D.M. ELISPOT assay to detect cytokine secreting murine and human cells. Coligan S.E., Kruisbeck A.M., Marguiles D.H., Shevach E.M., Strober W. Protocols in immunology. 1994;6.19.1-6.19.8 Wiley Interscience, New York.
24. Collins F.M. Protection afforded by BCG vaccines against aerogenic challenge by three mycobacteria of decreasing virulence. Tubercle. 66:1985;267-276.
25. Coffman R.L., Seymour B.W.P., Lebman D.A., Hirari D.D., Christiansen J.A., Shrader B., Cherwinski H.M., Savelkoul H., Finkelman F.D., Bond M.W., Mosmann T.R. The role of helper T cell products in mouse B differentiation and isotype regulation. Immunol. Reviews. 102:1988;5-28.
26. Seder R.A., Mossman T.M. Differentation of effector phenotypes of CD4+ and CD8+ T cells. Paul W. Fundamental immunology. 1993;879-908 Lippincott-Raven, Philadelphia.
27. Cooper A.M., Dalton D.K., Stewart T.A., Griffin J.P., Russell D.G., Orme I.M. Disseminated tuberculosis in interferon-γ disrupted mice. J. Exp. Med. 178:1993;2243-2247.
28. Flynn J.A., Chan J., Triebold K.J., Dalton D.K., Stewart T.A., Bloom B.R. An essential role for interferon-γ in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 178:1993;2249-2251.
29. North R.J., Medina E. How important is Nramp1 in tuberculosis? Trends Microbiol. 6:1998;441-443.
30. Zhu X., Venkataprasad N., Thangaraj H.S., Hill M., Singh M., Ivanyi J., Vordermeier H.M. Functions and specificity of T cells following nucleic acid vaccination of mice against Mycobacterium tuberculosis infection. J. Immunol. 158:1997;5921-5926.
31. Grifantini R., Finco O., Bartolini E., Draghi M., Delguidice G., Kocken C., Thomas A., Abrignani S., Grandi G. Multi-plasmid DNA vaccination avoids antigenic competition and enhances immunogenicity of a poorly immunogenic plasmid. Eur. J. Immunol. 28:1998;1225-1232.
32. Doolan D.L., Hoffman S.L. Multi-gene vaccination against malaria: a multistage, multi-immune response approach. Parasitol. Today. 13:1997;171-178.
33. Haigwood N.L., Pierce C.C., Robertson M.N., Watson A.J., Montefiori D.C., Rabin M., Lynch J.B., Kuller L., Thompson J., Morton W.R., Benveniste R.E., Hu S., Greenberg P., Mossman S.P. Protection from pathogenic SIV challenge using multigenic DNA vaccines. Immunol. Lett. 66:1999;183-188.
34. Florido M., Goncalves A., Silva R.A., Ehlers S., Cooper A., Appleberg R. Resistance of virulent Mycobacterium avium to gamma interferon-mediated activity suggests additional signals for induction of mycobacteriostasis. Infect. Immun. 67:1999;3610-3618.
35. Flynn J.L., Goldstein M.M., Chan J., Triebold K.J., Pfeffer K., Lowenstein C.J., Schreiber R., Mar T.W., Bloom B.R. Tumor necrosis factor-α is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity. 2:1995;561-572.
36. Stenger S., Hanson D.A., Teitelbaum R., Dewan P., Niazi K.R., Froelich C.J., Ganz T., Thomas-Vszynski S., Meliton A., Bogdan C., Porcelli S.A., Bloom B.R., Krensky A.M., Modlin R.L. An antimicrobial activity of cytotoxic T cells mediated by granulysin. Science. 282:1998;121-125.
37. Gurunathan S., Prussin C., Sacks D.L., Seder R.A. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nature Med. 4:1998;1409-1415.
38. Wu Y., Kipps T.J. Deoxyribonucleic acid vaccines encoding antigens with rapid proteosome-dependent degradation are highly efficient inducers of cytotoxic T lymphocytes. J. Immunol. 159:1997;6037-6043.
39. North R.J. Mycobacterium tuberculosis is strikingly more virulent for mice when given via the respiratory than via the intravenous route. J. Infect. Dis. 172:1995;1550-1553.
40. Cardona P.J., Cooper A., Luquin M., Ariza A., Filipo F., Orme I.M., Ausina V. The intravenous model of murine tuberculosis is less pathogenic than the aerogenic model owing to a more rapid induction of systemic immunity. Scand. J. Immunol. 49:1999;362-366.
41. Hamajima K., Sosaki S., Fukushima J., Kaneko T., Xin K., Kudoh I., Okunda K. Intranasal administration of HIV-DNA vaccine formulated with a polymer, carboxymethylcellulose, augments mucosal antibody production and cellular immune responses. Clin. Immunol. Immunopath. 88:1998;205-210.
42. Cooper A.M., Callahan J.E., Keen M., Belisle J.T., Orme I.M. Expression of memory immunity in the lung following re-exposure to Mycobacterium tuberculosis. Tubercle Lung Dis. 78:1997;67-73.